Frontlight ResearchEarly access
CompletedNo phase
Extended Depth of Focus (EDF) Intraocular Lens (IOL) Versus Monofocal Intracoular Lens (IOL)
Key facts
- Who runs it
- Carl Zeiss Meditec AG
- Where
- Bulgaria, Czechia, Romania, and Spain14 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 220 people enrolled
- Started
- 1 Oct 2025
- Ended
- 27 Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- EDF
- Monofocal IOL
- Record updated
- 17 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- Patients of any gender, aged 18 years or older
- Patient with clinically significant bilateral age-related cataracts planned for phacoemulsification cataract extraction and eligible for implantation of a posterior chamber intraocular lens as determined by investigator's medical judgement
- Preoperative keratometric (corneal) astigmatism of 1.00 D or less (≤1.00 D)
- Calculated lens power within the available range
- Clear intraocular media other than cataract
- Patient is willing and capable of providing informed consent
- Patient is willing and capable of complying with visits and procedures as defined by this protocol
Who cannot take part
- Previous intraocular or corneal/refractive surgery that might confound the outcome of the investigation or increase the risk to the patient (including corneal transplants, removal of pterygium, and LASIK, LASEK, PRK, RK limbal relaxing incision etc.)
- Current systemic or ocular pharmacotherapy that effects patients' vision with significant ocular side effects or any medications that could confound the outcome or increase subject risk
- Concurrent participation in another clinical investigation in the last 30 days
- Acute, chronic, or uncontrolled systemic disease that could increase the operative risk or confound the outcome including but not limited to poorly controlled diabetes mellitus, active cancer treatment, mental illness, dementia, immunocompromised, connective tissue disease, clinically significant atopic disease, etc
- Ocular condition that may predispose patient to future complications, per investigator's medical judgement, including but not limited to severe dry eye, anterior segment pathology, uncontrolled glaucoma, that would result in a visual acuity of 0.2 logMAR or worse during the study
- Clinically significant corneal abnormalities, including corneal dystrophy (epithelial, stromal or endothelial dystrophy), irregularity or oedema as per Investigator's medical judgement; conditions including but not limited to kerato-uveitis, keratopathy, keratectasia
- Any clinically significant condition that could affect IOL stability (e.g. zonular dialysis, evident zonular weakness or dehiscence, etc.)
- Patients with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders, optic nerve atrophy etc.) or any other pathologies of the eye that are predicted to result in a visual acuity of 0.2 logMAR or worse during the study
- History of or current anterior or posterior segment inflammation, including but not limited to iritis or uveitis
- Pregnant, plan to become pregnant, lactating during the course of the investigation, or another condition with associated fluctuation of hormones that could lead to refractive changes
- Endothelial cell count of less than 2000/mm2
- Preoperative corrected distance visual acuity (CDVA) better than 0.3 logMAR (0.5 decimal)
- Clinically significant gonioscopic abnormalities
- Amblyopia, strabismus, single eye status
- Rubella, congenital, traumatic or complicated cataracts
- Microphthalmos or macrophthalmos
- Pupil abnormalities (e.g. aniridia, abnormal shaped pupils, nonreactive pupils)
- Pseudoexfoliation
- Keratoconus or irregular astigmatism
- Inability to measure keratometry or biometry (including but not limited to cataract density, etc.)
- Pathologic miosis
- Patients unable to meet the limitations of the protocol or likely of non-cooperation during the trial
- Patients whose freedom is impaired by administrative or legal order
Where is this trial?
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Extended depth of focus (EDF) intraocular lens (IOL) versus Monofocal intraocular lens (IOL)
The 2 groups in the trial
- Extended depth of focus (EDF)Treatment being tested
Extended depth of focus
Treatment: EDF
- MonofocalExisting treatment, for comparison
Treatment: Monofocal IOL
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Randomized, Controlled, Observer-masked, Multi-center Clinical Trial to Demonstrate the Safety and Effectiveness of the Extended Depth of Focus AT LARA 829MP Posterior Chamber Intraocular Lens for Correction of Aphakia
- Record updated
- 17 August 2026